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INTRODUCTION: Approximately 35% of cases of Conn’s syndrome (primary aldosteronism) result from a
solitary functioning adrenal adenoma, and these patients are best managed by adrenalectomy. Postop-
erative hypoaldosteronism after unilateral adrenalectomy is uncommon.
CASE PRESENTATION: We present a case and literature review of hypoaldosteronism after unilateral
adrenalectomy for Conn’s syndrome, which demonstrates the insidious and sometimes delayed pre-
sentation.
DISCUSSION: In this clinical case we summarize the previously published cases of post-adrenalectomy
hypoaldosteronismbased on a PUBMEDandEBSCOhost search of all peer-reviewedpublications (original
articles and reviews) on this topic. A fewcases of aldosterone insufﬁciency post-adrenalectomy for Conn’s
syndrome were identiﬁed. The etiological factors for prolonged selective suppression of aldosterone
secretion after unilateral adrenalectomy remain unclear.
CONCLUSION: It is important to be aware of the risk of postoperative hypoaldosteronism in this patient
population. Close postoperative follow-up is necessary and strongly recommended, especially in patients
with certain risk factors. Patients may need mineralocorticoid supplementation during this period.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Primary aldosteronism (PA), or Conn’s syndrome, results from
unregulated release of excess aldosterone fromone or both adrenal
glands. Aldosterone-producing adenoma and bilateral idiopathic
hyperaldosteronism are the two most common subtypes of PA.
A much less common form, unilateral hyperplasia, is caused by
micronodular or macronodular hyperplasia of the zona glomeru-
losa of predominantly one adrenal gland [1]. Between 30 and 35%
of PA cases result from a solitary functioning adrenal adenoma [1]
and these patients are best managed by adrenalectomy. Postopera-
tively, some patients may experience transient hypoaldosteronism
requiring mineralocorticoid replacement, but this is an uncommon
scenario. Here, we present a case report and literature review of
hypoaldosteronism after unilateral adrenalectomy for PA.
2. Presentation of case
A 66-year-old female was referred for surgical manage-
ment of her PA in January 2012. The patient presented with a
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13-year history of hypertension and hypokalemia. On presenta-
tion, she was on nifedipine and triamterene/hydrochlorothiazide,
but her blood pressure remained elevated at 134/84mmHg. On
June 29th 2011 she had a serum aldosterone level of 688pmol/L
(normal 70–660) which was associated with a suppressed plasma
renin level of <0.05ng/L/s (normal 0.05–0.55) yielding an elevated
aldosterone/renin ratio of >13,760 (normal <2500). Her plasma
potassium at this time was 3.9mmol/L (normal 3.5–5.0mmol/L).
Soon after these results were received, spironolactone was added.
On August 12th 2011, she was taken off her triamterene and
spironolactone. At the same time she was started on potassium
supplementation and her potassium was closely followed.
On September 26th 2011, after she had been off the spironolac-
tone and triamterene for six weeks, she underwent conﬁrmatory
testing with a saline suppression test which was positive (post-
saline aldosterone 445pmol/L, normal <140pmol/L). A CT scan
revealed a 1.8 cm nodule in the left adrenal gland consistent with
an adenoma and a normal appearing right adrenal gland (Fig. 1).
She went on to have adrenal venous sampling on November 17th
2011which showedmarked left dominance in aldosterone produc-
tion with a lateralization index of 72.6, well above the commonly
employed threshold of 4 used to deﬁne lateralization [2].
In March 2012, she underwent an uneventful left retroperito-
neoscopic adrenalectomy. She was discharged home on the ﬁrst
http://dx.doi.org/10.1016/j.ijscr.2015.01.013
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license
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Fig. 1. CT image of left 1.8 cm adrenal nodule with an average attenuation of 2.6
Hounsﬁeld units.
postoperative day with a blood pressure of 135/71mmHg. She was
advised to continue her preadmission antihypertensives except for
spironolactone.
Grosspathologic examination revealedan18.3 gram left adrenal
gland measuring 6.0×3.5×1.5 cm with a 1.8 cm round, ﬁrm, and
well-circumscribed orange-tan nodule within the adrenal cortex
without areas of hemorrhage or degeneration. The residual adrenal
cortex appearedgrossly normalwithout signiﬁcant atrophy.Micro-
scopic sections of the nodule conﬁrmed the presence of a ﬁbrous
pseudocapsule at the expansive border of the tumor (Fig. 2). The
component cells had large pale-staining, lipid-rich cytoplasm and
smaller cells with relatively sparse lipid and lightly eosinophilic
cytoplasm. Nuclear pleomorphism, hyperchromasia, and mitotic
ﬁgures were absent (Fig. 3). These ﬁndings were consistent with
a benign adrenal adenoma. The microscopic examination of the
remaining adrenal cortex was normal, and there were no signs of
nodular hyperplasia.
At her ﬁrst follow-up appointment three weeks after
surgery, her nifedipine had been stopped and her tri-
amterene/hydrochlorothiazide halved. She was complaining
of lightheadedness and her blood pressure was 130/80mmHg. Her
plasma potassium without any supplementation was normal at
4.9mmol/L. Her remaining antihypertensives were discontinued.
At her next follow-up visit four weeks postoperatively, she had
ongoing lightheadedness and was found to be hypotensive with a
blood pressure of 102/72mmHg. Additionally, her potassium was
elevated at 6.1mmol/L and sodium was decreased at 132mmol/L
(normal 135–148). She was diagnosed with aldosterone deﬁciency
and started on aldosterone replacement (ﬂudrocortisone 0.1mg
daily). Her ﬂudrocortisone was successfully weaned over the
following months. By six months postoperatively she was off all
medication, her potassium had normalized to 4.2mmol/L and her
blood pressure also normalized to 122/72mmHg.
3. Discussion
We performed a literature review based on a search of
all peer-reviewed publications on PUBMED and EBSCO-
host databases. Our search terms included “aldosterone”,
Fig. 2. Low power view (2× objective) of an adenoma with expansive smooth bor-
ders (yellow arrow) sharply demarcated from the adjacent normal adrenal cortex
(black arrow).
“primary aldosteronism”, “adrenal adenoma”, “hyperaldos-
teronism”, “adrenalectomy”, “postoperative hyperkalemia”,
“postoperative hypoaldosteronism”, “hyperkalemia”, “hypoal-
dosteronism”, and “adrenal hypotension”. The search was not
restricted by date or language of publication.
After unilateral adrenalectomy for PA, some patients mani-
fest hyperkalemia postoperatively [3]. Some think this is due to
the inability of the remaining adrenal gland to secrete sufﬁcient
amounts of aldosterone immediately after surgery [3,4]. In 2010,
Huanget al [5]describeda caseof a62-year-oldmanwhopresented
with prolonged and severe hyperkalemia after laparoscopic left
adrenalectomy for an aldosteronoma. Two weeks after his surgery,
he was found to have hyperkalemia and volume depletion. His vol-
ume depletion was determined by poor skin turgor, ﬂat jugular
veins and postural hypotension. The patient ﬁndings of elevated
plasma renin activity and inappropriately low aldosterone in the
setting of normal plasma cortisol and adrenocorticotropic hormone
(ACTH) suggested hypoaldosteronism. They attributed the hypoal-
dosteronism to be due to defects in aldosterone biosynthesis or
selective unresponsiveness to angiotensin II in the adrenal zona
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Fig. 3. Highpower view (40×objective) demonstratingblandappearing large, lipid-
rich cells composing most of the adenoma.
glomerulosa. They suggested that their ﬁndings of dissociated renin
and aldosterone levels imply that contralateral aldosterone secre-
tion after unilateral adrenalectomy is not determined by feedback
control, but rather by the synthetic capability of the remaining
adrenal gland.
Gordon et al [6] showed a prolonged postoperative period of
up to 2 years in which patients no longer requiring antihyperten-
sive medications had evidence of intravascular volume depletion,
associated with low to low-normal serum aldosterone and high to
high-normal plasma renin activity, despite being off their antihy-
pertensive medication. This suggests a decreased adrenal mass as
being the potential cause for the postoperative hyperkalemia. This
is in contrast to the ﬁndings of Gadallah et al [7] who reported a
case in which severe hyperkalemia and hypotension were associ-
atedwith very low serumaldosterone levels. In this patient, plasma
renin activity was extremely low, suggesting suppression of the
juxtaglomerular apparatus of the kidneys. The gradual normaliza-
tion of hyperkalemia and the renin and aldosterone levels meant
this suppression was reversible.
Very low levels of aldosterone are usually seen transiently in
the postoperative period, and some published studies suggest that
the remaining adrenal gland produces normal aldosterone levels
by 6 months [8–11]. However, Gordon et al [6] concluded that the
tendency tohypotensionafterunilateral adrenalectomy is clinically
signiﬁcant and if left untreated, may not recover spontaneously.
This was based on a prospective evaluation of blood pressure and
hormone response to unilateral adrenalectomy for Conn’s syn-
drome in twenty-six patients seen at regular intervals for two
years postoperatively. At two years, seven patients (27%) had sys-
tolic blood pressures below the ﬁfth percentile which was more
than ﬁve times the expected rate. Mean plasma aldosterone lev-
els were signiﬁcantly lower than in age- and sex-matched controls
at 1 and 2 years postoperatively, suggesting relative aldosterone
deﬁciency.
Three weeks elapsed between our patient’s surgery and her
development of classical clinical features of aldosterone deﬁciency.
Similar to Morimoto et al., [12], this could be attributed to her pre-
operative spironolactone which may have a protective role. They
explain that preoperative spironolactone corrects the metabolic
derangements caused by excessive aldosterone, such as prolonged
hypervolemia. This prevents the juxtaglomerular apparatus from
being fully suppressed preoperatively and to resume normal func-
tion postoperatively.
In 2012, Fischer et al [13] sought to identify risk factors pre-
disposing to hyperkalemia post-adrenalectomy. They performed
a retrospective chart review and found that eighteen of their
110 patients who underwent adrenalectomy for PA developed
hyperkalemia. Six of these patients required mineralocorticoid
replacement therapy. They describe higher age and impaired
renal function as risk factors for postoperative hyperkalemia, and
found that preoperative treatmentwithmineralocorticoid receptor
antagonists did not inﬂuence the incidence of hypoaldosteronism
and hyperkalemia in their patients. Renal function as a risk factor
is a signiﬁcant ﬁnding because patients with PA have been shown
to be at a higher risk for earlier and prominent renal involvement
as compared to patients with essential hypertension [14]. Renal
impairment was not an issue in our patient as her creatinine and
eGFR had always been normal.
4. Conclusion
The case reported here highlights the importance of careful
postoperative follow up in Conn’s patients after adrenalec-
tomy. There is a described risk of aldosterone insufﬁciency that
may require mineralocorticoid supplementation. The reasons for
prolonged selective suppression of aldosterone secretion after
unilateral adrenalectomy remain unclear. Variables such as the
preoperative dose of spironolactone, the size of the adrenal mass,
the duration and severity of PA and the degree of hypokalemia
may be factors [5]. Some patients may have a decreased residual
adrenal mass. In this case the postoperative hypoaldosteronism
was transient; however, further studies to evaluate which patients
are at risk will prove useful. Though there are only a few case
reports of hypotension and hyperkalemia post-adrenalectomy,
the consequences of this if left undiagnosed can be severe. We
therefore recommend that all patients undergo close follow up
postoperatively and have their blood pressure, plasma potas-
sium and sodium, and serum aldosterone levels monitored. Older
patients and patients with preoperative impaired renal function
may require more prolonged monitoring.
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